Advertisement
UK markets closed

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     

  • AIM

    794.02
    +1.52 (+0.19%)
     

  • GBP/EUR

    1.1678
    +0.0023 (+0.20%)
     

  • GBP/USD

    1.2706
    +0.0035 (+0.28%)
     

  • Bitcoin GBP

    52,989.24
    -27.12 (-0.05%)
     

  • CMC Crypto 200

    1,368.50
    -5.34 (-0.39%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • DOW

    40,003.59
    +134.21 (+0.34%)
     

  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     

  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     
BRANDS:

Cornwall holiday lettings 'upstart' aims for £10m turnover

'We saw the niche and we grasped it'

Pfizer 1st-quarter sales disappoint, generics drag results

Reuters - UK Focus

May 5 (Reuters) - Pfizer Inc (NYSE: PFE - news) , the biggest U.S. drugmaker, on Monday reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.

Pfizer, which is trying to take over Britain's AstraZeneca (EUREX: AZNF.EX - news) Plc, earned $2.33 billion, or 36 cents per share, in the first quarter ended March 31. That compared with $2.75 billion, or 38 cents, in the year-earlier period, when the company reported gains from the transfer of product rights.

Excluding special items, Pfizer earned 57 cents per share. Analysts, on average, expected 55 cents per share, according to Thomson Reuters I/B/E/S.

Total (NYSE: TOT - news) revenues fell 9 percent to $11.35 billion, which was $730 million below Wall Street expectations.

Pfizer pulled its prior 2014 forecast, saying it will update its outlook its outlook "as soon as practicable." (Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)